Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Meseclazone has anti-inflammatory, analgesic, and antipyretic activity. Meseclazone shows inhibitory potency of secondary phase ADP aggregation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Meseclazone has anti-inflammatory, analgesic, and antipyretic activity. Meseclazone shows inhibitory potency of secondary phase ADP aggregation. |
In vivo | Intravenous administration of Meseclazone and other nonsteroidal anti-inflammatory drugs induced a dose-dependent inhibition of bronchoconstriction. This causing the following order of descending potency: isoproterenol congruent to indomethacin greater than fenoprofen greater than tolmetin greater than aspirin greater than naproxen congruent to ibuprofen greater than phenylbutazone greater than diflunisal greater than Meseclazone greater than 5-CSA. Meseclazone inhibits collagen-induced aggregation 1 and 4 hr after oral administration[1][2]. |
Synonyms | W2395, NSC297623 |
Molecular Weight | 239.65 |
Formula | C11H10ClNO3 |
CAS No. | 29053-27-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Meseclazone 29053-27-8 Neuroscience AChR W2395 W 2395 W-2395 NSC-297623 NSC297623 NSC 297623 inhibitor inhibit